Arava, Avandia's Divergent Paths: FDA Strengthens Arava Label Warning
This article was originally published in The Pink Sheet Daily
Executive Summary
As FDA advisory committee debated the fate of Avandia, the agency bolsters liver warning on Arava, another drug David Graham suggested be removed from the market.